Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Strengths of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01425814 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01425814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01425814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Strengths of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
March 31, 2012
Enrollment
87 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)